Biostatistics Shared Service | Biostatistics Services | Biostatistics Policies and Fees | Biostatistics Personnel | Biostatistics Contact Information | Biostatistics Publications | Biostatistics Software | Biostatistics Policies and Fees
Søren M. Bentzen, MSc, PhD, DMSc,Professor, Director of the Biostatistics Shared Service, University of Maryland Greenebaum Cancer Center, and Director of the Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland School of Medicine since 2013. Dr. Bentzen is also an Adjunct Professor of Radiobiology and Medical Physics, University of Copenhagen, Denmark. His previous appointments include MD Anderson Cancer Center (1987-1988), Danish Cancer Society/Aarhus University (1988-1997), Gray Laboratory/Mount Vernon Hospital, London (1998-2004), and University of Wisconsin School of Medicine and Public Health (2005-2013) where he was a professor of Human Oncology and held affiliate faculty positions in the departments of Biostatistics & Medical Informatics and in Medical Physics.
Dr. Bentzen received a MSc in physics and mathematics (1981), a PhD in medical image analysis (1986), and a DMSc (doctor of medical science) in quantitative clinical radiobiology (1994), all from Aarhus University, Denmark. He has published >370 original papers and book chapters, and has presented >300 invited lectures. He currently serves on 10 international cancer journal editorial boards. His research has been recognized by 24 awards and honors, including the ESTRO Breuer Gold Medal (2003), the MD Anderson Distinguished Alumnus Award (2008), and Honorary Life Memberships of the Association of Radiation Oncologists of India (2008) and the Belgian Society for Therapeutic Radiology and Oncology (2009). He held an Honorary Professorship at University College London (2000-2005) and was a Visiting Statistician to the Medical Research Council Clinical Trials Office, London, UK (1998-2004).
Dr. Bentzen is currently the principal investigator of a randomized controlled phase III trial of resource sparing radiation therapy for locally-advanced squamous cell carcinoma of the head and neck, sponsored by the International Atomic Energy Agency; member of the Previously-untreated Locally Advanced Disease Task Force of the Head and Neck Cancer Steering Committee of the National Cancer Institute (NCI); founding member of the Steering Committee of the International Radiogenomics Consortium; member of the UICC Global Task Force on Radiotherapy for Cancer Control; member of the Board of Directors of the International Commission on Radiation Units; member of the Steering Committee of PENTEC (PEdiatric Normal Tissue Effects in the Clinic) group. He was one of the leaders of the QUANTEC (Quantitative Analyses of Normal Tissue Effects in the Clinic) initiative (2007-2010) and member of the ASTRO Task Force to develop an evidence-based guideline on the appropriate fractionation for whole breast irradiation (2009-2010). He has served as chair or member of 17 (seven currently active) Independent Data and Safety Monitoring Committees or Trial Steering Committees. He is co-chair for Translational Research for two open RTOG phase III trials.
His main research interests include bioeffect modeling; biomathematics; applied biostatistics; clinical trial design; evidence-based medicine; late effects of radiotherapy; clinical radiobiology; integration of data from genomics, proteomics, and molecular imaging into novel therapeutic strategies.
Olga Goloubeva, Ph.D., M.Sc., is a UMGCC faculty biostatistician, an Associate Professor, Department of Epidemiology and Public Health, University of Maryland School of Medicine. Dr. Goloubeva received her Ph.D. in engineering. She continued her graduate training in mathematical statistics and in 1999 earned a Master's degree in mathematical statistics from Dalhousie University, Halifax, Canada. She was an assistant professor in the Department of Mathematics and Computer Studies at the Mount Saint Vincent University, Halifax, Canada (1993-1999). In 1999, she joined St. Jude Children's Research Hospital Cancer Center as a biostatistician, where she collaborated with investigators in virology, diagnostic imaging, and radiation oncology. In 2001, Dr. Goloubeva moved to Dana Farber Cancer Institute, Boston, MA, where she collaborated as a biostatistician in CLL Consortium, the Leukemia Committee for ECOG, and the AIDS Immunology Group.
She joined UMGCC in 2003 and has been involved in collaborative research throughout the center, including areas in breast, prostate, lung, head and neck cancer, myeloma, radiation oncology, and cancer disparities. She is currently a member of the Cancer Center Clinical Protocol Review Committee, the UMGCC Tissue Bank Committee, the DSMQAC, UMGCC and a member of the center's Hormone Responsive Cancers Program. She is a member of the UM DSM Board for Pediatrics Study of Lactobacillus. Dr.Goloubeva is a member of the NIA IRP Scientific Review Committee and two DSM Boards for NIH/NIA phase I and II clinical trials. She served as an International Topical Expert (Biostatistics & Bioinformatics) and a Voting Member for the cancer center site visit in Innsbruck, Austria. Her statistical expertise lies in the design and analysis of preclinical studies and clinical trials, evaluation of diagnostic tests, biomarkers and their combination, prognostic models of cancer and other diseases, longitudinal and hierarchical data modeling. The ongoing collaboration in research of many different cancers and diseases is reflected in her > 80 peer-reviewed publications.